Granahan Investment Management LLC Decreases Stock Holdings in OrthoPediatrics Corp. (NASDAQ:KIDS)

Granahan Investment Management LLC lowered its stake in OrthoPediatrics Corp. (NASDAQ:KIDS) by 22.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 786,369 shares of the company’s stock after selling 223,890 shares during the quarter. Granahan Investment Management LLC owned 3.25% of OrthoPediatrics worth $18,228,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Deutsche Bank AG boosted its stake in OrthoPediatrics by 57.1% during the 4th quarter. Deutsche Bank AG now owns 14,393 shares of the company’s stock worth $334,000 after purchasing an additional 5,233 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in OrthoPediatrics during the fourth quarter worth about $461,000. Northern Trust Corp grew its stake in OrthoPediatrics by 0.3% during the 4th quarter. Northern Trust Corp now owns 193,798 shares of the company’s stock valued at $4,492,000 after acquiring an additional 644 shares in the last quarter. Tudor Investment Corp ET AL raised its holdings in OrthoPediatrics by 177.5% in the 4th quarter. Tudor Investment Corp ET AL now owns 66,486 shares of the company’s stock valued at $1,541,000 after acquiring an additional 42,526 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in OrthoPediatrics by 29.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 671,968 shares of the company’s stock worth $15,576,000 after purchasing an additional 152,681 shares in the last quarter. Hedge funds and other institutional investors own 69.05% of the company’s stock.

Insider Buying and Selling

In other OrthoPediatrics news, CEO David R. Bailey sold 6,620 shares of the stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $164,573.20. Following the sale, the chief executive officer now directly owns 319,155 shares in the company, valued at $7,934,193.30. This represents a 2.03 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Fred Hite sold 6,443 shares of the business’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $160,172.98. Following the completion of the transaction, the chief financial officer now owns 207,989 shares of the company’s stock, valued at approximately $5,170,606.54. This trade represents a 3.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 23,732 shares of company stock valued at $589,978. Corporate insiders own 32.70% of the company’s stock.

Wall Street Analyst Weigh In

KIDS has been the subject of a number of analyst reports. Needham & Company LLC restated a “buy” rating and issued a $42.00 price target on shares of OrthoPediatrics in a research report on Thursday. Piper Sandler cut their target price on OrthoPediatrics from $40.00 to $30.00 and set an “overweight” rating for the company in a research note on Thursday. Lake Street Capital initiated coverage on OrthoPediatrics in a report on Monday, April 7th. They set a “buy” rating and a $37.00 price target on the stock. Truist Financial dropped their price objective on shares of OrthoPediatrics from $26.00 to $24.00 and set a “hold” rating for the company in a report on Friday, April 11th. Finally, Stifel Nicolaus reduced their target price on shares of OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, March 5th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $35.83.

OrthoPediatrics Stock Down 4.5 %

Shares of KIDS opened at $22.04 on Friday. The company’s 50-day moving average price is $23.08 and its 200 day moving average price is $24.09. OrthoPediatrics Corp. has a 12-month low of $20.25 and a 12-month high of $35.99. The company has a current ratio of 7.17, a quick ratio of 3.68 and a debt-to-equity ratio of 0.19. The firm has a market cap of $535.29 million, a P/E ratio of -17.92 and a beta of 1.09.

OrthoPediatrics (NASDAQ:KIDS) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.13). OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. The company had revenue of $52.41 million during the quarter, compared to analysts’ expectations of $51.68 million. On average, sell-side analysts forecast that OrthoPediatrics Corp. will post -0.93 earnings per share for the current year.

OrthoPediatrics Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.